MedKoo Cat#: 575200 | Name: AZD1446 tosylate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AZD1446, also known as TC-6683, is a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. AZD1446 showed favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and had been evaluated in phase 2 clinical trials as a treatment for Alzheimer's disease.

Chemical Structure

AZD1446 tosylate
AZD1446 tosylate
CAS#1392330-84-5 (tosylate)

Theoretical Analysis

MedKoo Cat#: 575200

Name: AZD1446 tosylate

CAS#: 1392330-84-5 (tosylate)

Chemical Formula: C18H21ClN2O5S

Exact Mass: 0.0000

Molecular Weight: 412.89

Elemental Analysis: C, 52.36; H, 5.13; Cl, 8.59; N, 6.78; O, 19.37; S, 7.76

Price and Availability

Size Price Availability Quantity
5mg USD 250.00 Ready to Ship
10mg USD 450.00 Ready to Ship
25mg USD 950.00 Ready to Ship
50mg USD 1,650.00 Ready to Ship
100mg USD 2,950.00 Ready to Ship
Bulk Inquiry
Buy Now
Add to Cart
Synonym
AZD1446 tosylate; AZD 1446, AZD-1446, AZD1446, TC 6683, TC-6683, TC6683
IUPAC/Chemical Name
3-(5-Chloro-2-furoyl)-3,7-diazabicyclo(3.3.0)octane tosylate
InChi Key
GWTRGLDVMRLRSS-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H13ClN2O2.C7H8O3S/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14;1-6-2-4-7(5-3-6)11(8,9)10/h1-2,7-8,13H,3-6H2;2-5H,1H3,(H,8,9,10)
SMILES Code
O=C(N1CC2CNCC2C1)C3=CC=C(Cl)O3.OS(=O)(C4=CC=C(C)C=C4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
AZD1446, also known as TC-6683, is a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.
In vitro activity:
TBD
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 412.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Vogt BA. Cingulate impairments in ADHD: Comorbidities, connections, and treatment. Handb Clin Neurol. 2019;166:297-314. doi: 10.1016/B978-0-444-64196-0.00016-9. PMID: 31731917. 2: Zimmerman CN, Eskow Jaunarajs KL, Meringolo M, Rizzo FR, Santoro M, Standaert DG, Pisani A. Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia. Front Syst Neurosci. 2017 Jun 13;11:43. doi: 10.3389/fnsys.2017.00043. PMID: 28659770; PMCID: PMC5468415. 3: Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16(2):131-44. doi: 10.1586/14737175.2016.1135735. Epub 2016 Jan 14. PMID: 26693882. 4: Boström E, Bohnstedt KC, Jostell KG, Alverlind S, Huledal G, Paulsson B, Hårdemark HG, Öhd J, Lindholm S. Population pharmacokinetics and safety of AZD1446, a neuronal nicotinic receptor agonist, administered in healthy volunteers. Clin Pharmacol Drug Dev. 2014 Jan;3(1):63-71. doi: 10.1002/cpdd.59. Epub 2013 Sep 9. PMID: 27128232. 5: Jucaite A, Öhd J, Potter AS, Jaeger J, Karlsson P, Hannesdottir K, Boström E, Newhouse PA, Paulsson B. A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2014 Mar;231(6):1251-65. doi: 10.1007/s00213-013-3116-7. Epub 2013 May 3. PMID: 23640072; PMCID: PMC3838503. 6: Mazurov AA, Miao L, Bhatti BS, Strachan JP, Akireddy S, Murthy S, Kombo D, Xiao YD, Hammond P, Zhang J, Hauser TA, Jordan KG, Miller CH, Speake JD, Gatto GJ, Yohannes D. Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. J Med Chem. 2012 Nov 8;55(21):9181-94. doi: 10.1021/jm3006542. Epub 2012 Jul 27. PMID: 22793665.